Cargando…
FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis
Background: Fibroblast growth factor-23 (FGF-23) is a hormone principally produced by osteocytes/osteoblasts. In patients with chronic kidney disease (CKD), FGF-23 levels are usually elevated and can reach up to 300 – 400 times the normal range. FGF-23 is regulated by local bone-related and systemic...
Autores principales: | Lima, Florence, El-Husseini, Amr, Monier-Faugere, Marie-Claude, David, Valentin, Mawad, Hanna, Quarles, Darryl, Malluche, Hartmut H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535177/ https://www.ncbi.nlm.nih.gov/pubmed/25208316 http://dx.doi.org/10.5414/CN108407 |
Ejemplares similares
-
FGF-23 and sclerostin in serum and bone of CKD patients
por: Lima, Florence, et al.
Publicado: (2023) -
Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
por: Lima, Florence, et al.
Publicado: (2019) -
Diagnosis of low bone mass in CKD-5D patients
por: Blomquist, Gustav A., et al.
Publicado: (2016) -
Prevalence of low bone formation in untreated patients with osteoporosis
por: Malluche, Hartmut H., et al.
Publicado: (2022) -
Response to “Low Turnover Bone Disease in Early CKD Stages”
por: El-Husseini, Amr, et al.
Publicado: (2022)